Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
114.23
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.
Via
InvestorPlace
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
November 15, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the
Via
Benzinga
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
The biotech has what it takes to overcome recent obstacles.
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 02, 2023
Via
Benzinga
Why Sarepta Therapeutics Stock Is Crashing Today
October 31, 2023
There's a plot twist with Sarepta's disappointing clinical results.
Via
The Motley Fool
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
November 09, 2023
Analysts still expect some sizable returns from the stock.
Via
The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
Just because a stock is "on sale" doesn't inherently make it worth purchasing.
Via
The Motley Fool
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
November 07, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
November 02, 2023
SRPT earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 01, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
October 31, 2023
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.
Via
Benzinga
Earnings Scheduled For November 1, 2023
November 01, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Via
Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
October 31, 2023
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to
Via
Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 31, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 31, 2023
Via
Benzinga
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
October 31, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Near Top of Volume Charts in Tuesday Trading
October 31, 2023
Via
Investor Brand Network
Why Are Stocks Down Today?
October 31, 2023
Stocks are down today and investors wondering why have come to the right place as we have an answer to that question!
Via
InvestorPlace
BB Stock Alert: What to Know as BlackBerry Announces CEO Departure
October 31, 2023
BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week.
Via
InvestorPlace
US Stocks Fall; Pfizer Swings To Q3 Loss
October 31, 2023
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
October 31, 2023
Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial.
Via
InvestorPlace
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
October 31, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.